1. Introduction {#s0025}
===============

Neurological features usually dominate the clinical presentation of patients harbouring the m.3243A\>G mitochondrial DNA (mtDNA) mutation; with migraine, encephalopathy, seizures, stroke-like episodes, deafness, ophthalmoplegia and myopathy all being common. Although well recognised in advanced cases [@b0005], cardiomyopathy is often overlooked, despite being a major cause of morbidity and mortality [@b0010; @b0015], and it may explain the increased rate of sudden unexpected death observed in Finnish patients harbouring m.3243A\>G [@b0020]. Using relatively insensitive 2D-echocardiography, left-ventricular hypertrophy was been detected in 56% of cases [@b0010], raising the possibility that cardiac dysfunction is major feature of the disorder potentially amenable to early treatment to prevent cardiac failure [@b0025]. To address this issue, we used cardiac magnetic resonance imaging (MRI) to determine the prevalence of cardiac dysfunction in m.3243A\>G mutation carriers, with contemporaneous genetic and biochemical studies on skeletal muscle to elucidate the mechanism.

2. Methods {#s0030}
==========

We studied ten m.3243A\>G mutation carriers (five male, five female, mean age 42.5 ± SD 9 years). [Tables 1 and 2](#t0005 t0010){ref-type="table"} shows the clinical and laboratory data, including co-morbidities and medication), and sixteen healthy age matched controls (eight male, eight female, mean age 41.6 ± SD 15 years). No significant abnormalities were found on electrocardiography (ECG) or 2D-echocardiography in either group. Systolic and diastolic blood pressure was normal. Nine m.3243A\>G mutation carriers underwent a left vastus lateralis skeletal muscle needle biopsy. Respiratory chain complex activities, and the level of m.3243A\>G mutation were determined in each biopsy as described [@b0030], along with the mutation load in urinary epithelium and blood when available.

3-Tesla ECG-gated cardiac MRI was performed using a six-channel cardiac coil on supine subjects (Philips Intera Achieva, Best, NL). Structural evaluation included left ventricular (LV) mass relative to body surface area, ejection fraction, end-systolic and end-diastolic volumes. The eccentricity ratio was calculated as the ratio of LV mass to end-diastolic volume and an increase in this parameter was interpreted as evidence of concentric remodelling. Cardiac tagging was used to evaluate function measured as torsion and regional myocardial strains: these include the torsion-to-endocardial strain ratio, a measure of the relative contribution of the endocardial and epicardial contractions to systole; and radial thickening, the percentage increase in average wall thickness from end-diastole to systole ([Detailed MRI methods described on-line](#s0050){ref-type="sec"}). Written informed consent was obtained from all participants and institutional ethics was obtained.

3. Results {#s0035}
==========

All m.3243A\>G patients had structural and functional cardiac abnormalities on MRI when compared to age-matched controls ([Table 3](#t0015){ref-type="table"}. [Online videos](#s0050){ref-type="sec"}). These included, increased LV index (74 g/m^2^ vs. 59 g/m^2^, *p* = 0.001), reduced end systolic (36 ml vs. 61 ml, *p* = 0.0005) and diastolic volume (103 ml vs. 143 ml, *p* = 0.002), increased peak torsion (7.3° vs. 6.0° , *p* = 0.02) and an increased eccentricity ratio (1.19 g/ml vs 0.74 g/ml, *p* = 0.001, [Fig. 1](#f0005){ref-type="fig"}), indicative of cardiac remodelling. The percentage level of m.3243A\>G mutation in skeletal muscle correlated with the decrease in respiratory chain complex I activity (*κ* = 0.71, *p* = 0.01); and both muscle mutation load and complex I activity correlated with the torsion to endocardial strain ratio (*κ* = 0.71, *p* \< 0.05 and *κ* = −0.73, *p* \< 0.03, respectively), and with reduced radial thickening (*κ* = −0.80, *p* = 0.01, [Fig. 1](#f0005){ref-type="fig"}).

4. Discussion {#s0040}
=============

We found structural and functional cardiac abnormalities in all of the m.3243A\>G patients we studied. The major findings were: (1) concentric left ventricular hypertrophy in the absence of systemic hypertension; and (2) a re-orientation of myocardial strains with reduced longitudinal shortening and increased torsion. These findings indicate that sub-clinical cardiomyopathy is common in m.3243A\>G patients, and may be a universal finding. Although the majority of subjects in our study had clinical features of mtDNA disease, one was an asymptomatic carrier who also had abnormal cardiac function on MRI. Given previous reports of progressive cardiac hypertrophy leading to irreversible dilated cardiomyopathy in m.3243A\>G patients [@b0035], our observations re-enforce the importance of cardiac monitoring in all m.3243A\>G mutation carriers. Cardiac MRI provides a sensitive method of detecting early cardiac dysfunction, complementing echocardiography. Early intervention may reduce cardiac remodelling in m.3243A\>G patients and thus delay left ventricular failure, although this needs to be prospectively studied.

Despite known differences in tissue mutation load, we observed a correlation between the percentage level of m.3243A\>G and complex I activity in skeletal muscle, and several key cardiac measures of early cardiac dysfunction. When taken together, these observations support a central role for the genetic and biochemical defect in the pathogenesis of the cardiomyopathy, rather than an indirect mechanism through reduced physical fitness or co-morbidity related to the diabetes known to occur in m.3243A\>G carriers.

It remains intriguing that the two lowest muscle mutation levels were observed in a 31 year old patient without symptoms (m.3243A\>G = 24%) and in a 46 year old patient with a severe MELAS phenotype (m.3243A\>G = 26%). These findings reflect the known poor correlation between muscle mutation load and neurological phenotype; and contrast with the correlation that we observed between skeletal muscle mutation load and the degree of cardiac dysfunction. By inference, this implies that mutation load in myocardium is closely related to mutation load in skeletal muscle, and that the consequences of a given mutation level are similar in both cardiac and skeletal muscle. The same does not appear to be the case for the central nervous system, where there is a much more diverse range of cell types of different embryological origins, each responding to a given level of m.3243A\>G to differing degrees, and contributing to the combined neurological phenotype in different ways. The lack of any correlation between blood mutation levels and the cardiac phenotype is not surprising, given that m.3243A\>G in blood decreases with age [@b0040], unlike other tissues [@b0045].

Our observations also suggest that measures aimed at reducing mutation load or improving complex I activity are likely to be beneficial for the cardiomyopathy in m.3243A\>G patients. Although there are currently no known methods of reducing cardiac mutation load, it is conceivable that "gene shifting" techniques currently being explored in skeletal muscle could be of benefit [@b0050]. This would involve the delivery or local activation of cardiomyocyte precursors potentially harbouring a lower mutation load. An alternative approach could involve drugs known to increase mitochondrial biogenesis which could improve both the genetic and biochemical defect in a similar way to aerobic exercise in skeletal muscle [@b0055]. Interestingly, we saw no correlation between m.3243A\>G mutation load, complex I activity, or cardiac dysfunction and the specific enzyme activities of complex II and citrate synthase ([Table 2](#t0010){ref-type="table"}). These enzymes are considered to be markers of mitochondrial proliferation and biogenesis, suggesting that compensatory mitochondrial proliferation had not been activated in the skeletal muscle of the patients described here, despite the complex I defect. Finally, treatment with anti-oxidant drugs provides hope of treatment in the short term. The anti-oxidant properties of idebenone may explain the beneficial effects of this drug on the cardiomyopathy in Friedreich's ataxia, which also has a mitochondrial basis. The approach we describe here provides an objective method for assessing the efficacy of novel treatments in patients with m.3243A\>G. This will hopefully lead to the first cardioprotective therapy for primary mitochondrial disease.

Appendix A. Supplementary data {#s0050}
==============================

Supplementary data 1Structural Cardiac Magnetic Resonance Cine Imaging.Supplementary video 2Supplementary video 3
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###### 

Clinical data for the patients harbouring m.3243A\>G. It was not possible to obtain a muscle biopsy from subject 10.

  No.   Age (years)   Sex   Clinical features                    Medication           Echo LVEF (%)
  ----- ------------- ----- ------------------------------------ -------------------- ---------------
  1     55            M     Deafness, diabetes, ht, ha           ACEi, a, m, In, St   66
  2     48            M     Deafness, diabetes, ha               ACEi, St, In         70
  3     46            M     Deafness, hc, seizures, SLEs.        c, a, ACEi, St       55
  4     34            F     Deafness, constipation, ha           --                   \>60
  5     44            M     Migraine, constipation               f, a                 61
  6     42            F     Deafness, diabetes, ht, SLEs         z, ACEi              \>55
  7     55            F     Constipation, ha; asthma             --                   \>55
  8     30            F     Deafness, diabetes, ht, hcl, SLEs.   pr, St, c, In, le    \>60
  9     31            M     None                                 --                   60
  10    40            F     Deafness, diabetes                   --                   n/a

*Key:* ha = headaches, hc = hypercholesterolaemia, ht = hypertension, ACEi = angiotensin converting enzyme inhibitor, St = statin ± ezetmibe, ln = insulin, a = aspirin, m = metformin, c = carbamazepine, f = flunarazine, z = Na val, pr = propanolol, le = levemenre. SLEs: stroke-like episodes.

###### 

Molecular genetic and biochemical data for the patients harbouring m.3243A\>G. The percentage level of m.3243A\>G and respiratory chain complex activities were measured as previously described.

  No.   3243A\>G mutation load   I/mg   II/mg   III/mg   IV/mg   CS/mg             
  ----- ------------------------ ------ ------- -------- ------- -------- -------- --------
  1     62                       66     nd      0.623    1.017   5.613    7.891    6.393
  2     81                       nd     nd      0.284    0.881   8.185    4.966    7.128
  3     26                       82     28      1.354    2.061   17.294   21.440   9.116
  4     67                       80     26      0.645    3.237   21.716   17.507   11.628
  5     46                       48     5       0.626    1.344   8.861    9.589    6.421
  6     52                       nd     nd      1.176    4.710   34.082   28.429   21.743
  7     60                       20     9       1.126    2.367   14.938   19.049   13.412
  8     93                       86     3       0.207    1.807   13.000   4.939    18.911
  9     24                       34     7       1.530    2.155   16.711   16.024   12.584
  10    73                       57     21      --       --      --       --       --

The percentage level of m.3243A\>G and respiratory chain complex activities were measured as previously described. It was not possible to obtain a muscle biopsy from subject 10. CS = citrate synthase activity, nd = not determined. SKM = skeletal muscle, UE = urinary epithelium, BLD = blood.

###### 

Cardiac morphology and function parameters for controls and mutation carriers. LV = left ventricle.

  Parameter                                   Controls       m.3243A\>G     *p* value
  ------------------------------------------- -------------- -------------- -----------
  Age (years)                                 41.6 ± 15      42.5 ± 9       ns
  Heart rate (bpm)                            61 ± 13        71 ± 12        ns
  Systolic blood pressure (mm Hg)             128 ± 13       130 ± 14       ns
  Diastolic blood pressure (mm Hg)            76 ± 10        83 ± 10        ns
  Height (cm)                                 171 ± 11       165 ± 11       ns
  Weight (kg)                                 75 ± 10        63 ± 16        0.02
  Body Surface Area (BSA, m^2^)               1.8 ± 0.1      1.6 ± 0.2      ns
                                                                            
  *LV mass and global systolic function*                                    
  LV mass (g)                                 106.7 ± 20.4   119.7 ± 29.6   ns
  LV index \[LV mass/BSA\] (g/m^2^)           59.3 ± 9.5     73.7 ± 9.9     0.001
  Stroke volume (ml)                          82 ± 15        67 ± 16        0.02
  End-diastolic volume (ml)                   143.0 ± 32.0   103.1 ± 23.3   0.002
  End-systolic volume (ml)                    61.0 ± 18.7    36.2 ± 10.8    0.0005
  Ejection fraction (%)                       58 ± 5         65 ± 6         0.004
  Eccentricity ratio \[LV mass/EDV\] (g/ml)   0.74 ± 0.11    1.19 ± 0.30    0.001
                                                                            
  *LV strains*                                                              
  Longitudinal shortening (%)                 18.1 ± 2.8     14.5 ± 4.0     0.01
  Peak torsion (degrees)                      6.0 ± 1.4      7.3 ± 1.3      0.02
  Peak circumferential strain (%)             17.8 ± 2.7     17.5 ± 2.7     ns
  Radial thickening (%)                       59 ± 20        65 ± 23        ns
  Torsion to endocardial strain ratio (rad)   0.49 ± 0.13    0.57 ± 0.14    ns
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